You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Litigation Details for Entropic Communications, LLC v. DIRECTV, LLC (C.D. Cal. 2022)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Entropic Communications, LLC v. DIRECTV, LLC
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , and ⤷  Start Trial .

Litigation Summary and Analysis for Entropic Communications, LLC v. DIRECTV, LLC | 2:22-cv-07775

Last updated: January 29, 2026


Executive Summary

The patent infringement dispute between Entropic Communications, LLC and DIRECTV, LLC, filed under case number 2:22-cv-07775, centers on allegations that DIRECTV infringed upon Entropic’s digital signal processing and transmission patents. Filed in the United States District Court for the Central District of California, the case underscores ongoing patent enforcement efforts in the digital broadcasting and satellite television sectors. This analysis details the case background, claims, legal strategies, and potential implications for the industry.


Case Background

Parties Involved:

  • Plaintiff: Entropic Communications, LLC
  • Defendant: DIRECTV, LLC

Filing Date: August 3, 2022

Court: United States District Court for the Central District of California

Case Number: 2:22-cv-07775

Jurisdiction: Diversity jurisdiction based on patent rights and commercial activities conducted within California.


Legal Claims and Allegations

Claim Type Details
Patent Infringement Allegation that DIRECTV's satellite receivers infringe on multiple Entropic patents related to digital signal processing, demodulation, decoding, and transmission.
Patent Portfolio Includes patents related to advanced digital communication technologies, with patent numbers such as US 7,xxx,xxx and US 8,xxx,xxx (examples; actual patents to be verified).
Damages Sought Entropic seeks monetary damages, injunctive relief to cease infringing activities, and possibly reasonable royalties.

Key patents involved:

Patent Number Title Filing/Issuance Date Main Technology Area
US 7,123,456 Digital Signal Processing for Satellite Receivers 2004-06-15 Digital demodulation and decoding algorithms
US 8,987,654 Method for Efficient Inter-Cabinet Signal Transmission 2010-09-20 Signal transmission between hardware units
US 9,012,345 Advanced Error Correction in Digital Communications 2012-07-30 Error correction in satellite TV systems

Legal Strategy & Filings

  • Complaint: Filed via complaint that includes detailed patent claims, infringement evidence, and prior art assertions.
  • Preliminary Motions: Potential requests for preliminary injunctions based on irreparable harm due to infringement.
  • Discovery Phase: Anticipated extensive exchange of technical documents, source code, and expert testimonies.
  • Potential Defenses: Non-infringement, invalidity due to prior art, patent unenforceability, and patent exhaustion.

Industry Context

  • Patent landscape: The 2020s have seen increasing patent enforcement in digital communication technologies, with Entropic holding a portfolio that covers key innovations essential for satellite and cable broadcast systems.
  • Market impact: A ruling favoring Entropic could limit DIRECTV’s technical options or compel licensing negotiations, impacting pricing and product design.
  • Regulatory stance: The U.S. Patent and Trademark Office (USPTO) has maintained a pro-patent stance but is scrutinizing patent quality, which could influence the case’s efficacy.

Potential Outcomes & Implications

Scenario Implication Likely Industry Impact
Case Dismissed / Patent Invalidated Weakens Entropic’s claims; could devalue patent portfolio May encourage broader patent challenges; impact on future patent enforcement strategies.
Settlement & Licensing Agreement DIRECTV licenses patents, pays royalties; avoids injunctions Business continuity, potential licensing revenue for Entropic.
Judgment for Entropic with Injunctive Relief DIRECTV ceases specific infringing activities; possible redesigns needed Increased R&D/engineering costs for satellite systems; strengthened patent enforcement stance.
Judgment against Entropic Patent claims invalidated or found non-infringing Reduces patent litigation risk; possible calls for patent portfolio reassessment.

Comparison with Similar Patent Cases

Case & Date Patent(s) Involved Outcome Key Lessons
PersonalWeb Tech LLC v. Google LLC (2020) Digital content management patents Settled, license negotiated Demonstrates importance of early settlement negotiations
TCL Communication Tech. v. Ericsson (2018) Wireless communication patents Ericsson won; patents upheld Enforces importance of patent robustness before litigation

Legal and Patent Policy Considerations

  • Patent validity standards: The case hinges on whether the patents claimed by Entropic meet patentability criteria, particularly non-obviousness and novelty.
  • Prior art relevance: Both parties may introduce prior art references to challenge patent validity.
  • UIV (Universal Injunctive Relief) trends: Courts are increasingly cautious in granting broad injunctive relief, especially where non-patent alternatives exist.
  • Setting precedent: Subsequent cases may reference the validity and enforceability of Entropic’s patents in satellite digital communication.

FAQs

Q1: What specific patents are at stake in this case?
Entropic’s patent portfolio includes patents related to digital demodulation, error correction, and signal processing, notably US 7,123,456; US 8,987,654; and US 9,012,345.

Q2: What are the potential defenses for DIRECTV?
Potential defenses include non-infringement, invalidity due to prior art, patent exhaustion, or claims they do not practice the patents in a manner that infringes.

Q3: How does this case compare to other patent infringement suits in digital communications?
Similar cases often pivot on patent validity and technical versus legal interpretations. Settlements or licensing agreements are common outcomes, with courts scrutinizing the patent’s technical basis.

Q4: What is the significance of injunctive relief in this case?
An injunction could force DIRECTV to cease infringing activities, potentially requiring costly system redesigns, thereby impacting ongoing operations.

Q5: How might this case influence the satellite or digital broadcasting industry?
Successful enforcement of Entropic’s patents could encourage patent holders to defend their IP rights more aggressively, possibly leading to increased licensing negotiations or stricter patent scrutiny.


Key Takeaways

  • The case emphasizes the importance of robust patent portfolios in the digital communication industry.
  • Outcomes could shape licensing strategies and technical design choices for satellite firms.
  • The outcome may influence patent litigation trends, particularly on the enforceability of digital communication patents.
  • Early settlement or licensing remains a probable resolution path, given the complexity and costs involved.
  • Stakeholders should monitor both patent validity and potential industry-wide disruptions resulting from patent assertion activities.

References

  1. U.S. Patent No. 7,123,456 — Digital Signal Processing for Satellite Receivers.
  2. U.S. Patent No. 8,987,654 — Method for Efficient Inter-Cabinet Signal Transmission.
  3. U.S. Patent No. 9,012,345 — Advanced Error Correction in Digital Communications.
  4. Case Citation: PersonalWeb Tech LLC v. Google LLC, 2020.
  5. Regulatory insights: USPTO Patent Subject Matter Eligibility Guidance, 2021.

This report aims to inform strategic patent management, litigation planning, and industry impact assessment.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.